BIOQUELL Worldwide
IN THE NEWS
Directors' Dealings - Purchase of Shares
Appointment of Sir Ian Carruthers OBE as a Non-Executive Director Bioquell PLC – 2010 interim results Results of Bioquell PLC AGM Interim Management Statement Annual Report 2009 Press Release Notice of Annual General Meeting 2010 and form of Proxy BIOQUELL delivers strong growth in revenues and profit in 2009 Interim Management Statement Notification of major interest BIOQUELL PLC - Sale of Shares Award by the NHS Purchasing and Supply Agency to BIOQUELL BIOQUELL PLC - 2009 interim results DoH & PASA Publish report on Success of BIOQUELL System in Showcase Hospital Programme Results of AGM Proxy Voting May 2009 AGM Results Notice Results of AGM Proxy voting Notice of Annual General Meeting Interim Management Statement Directors’ exercise of options and acquisition of Shares Grant of options to Directors Annual Report 2008 BIOQUELL delivers strong growth in pre-tax profit and cash in 2008 BIOQUELL takes top prize at the Department of Health HCAI Technology Innovation Summit 2008 Interim Results Purchase of ordinary shares Directors’ dealings – purchase of Shares Results of AGM Proxy voting, Results of EGM Proxy voting, Results of Separate Class Meeting Proxy voting BIOQUELL PLC EGM - Cancellation of Share Premium Account Adoption of New Articles of Association & Amendment of the BIOQUELL Share Option Schemes PLC PRESS RELEASE: 2007 Preliminary Results PRESS RELEASE: Award of Joint Material Decontamination System Sub-Contract |
TO: CITY EDITORS 2 October, 2007 BIOQUELL PLC Award of Joint Material Decontamination System BIOQUELL PLC (“BIOQUELL”), the UK leader in specialist bio-decontamination technology and testing/compliance services, announces that it is a member of the Teledyne Brown Engineering, Inc. (“TBE”) Team that has been awarded a contract relating to the United States Department of Defense (“DOD”) Joint Material Decontamination System (“JMDS”). The JMDS is required to have the ability to decontaminate sensitive equipment, and interiors of vehicles, aircraft, ships and fixed site facilities that have been exposed to Chemical, Biological, Radiological and Nuclear (“CBRN”) warfare agents. Users of the JMDS will include the United States Army, Navy, Air Force and Marine Corps. TBE has informed BIOQUELL that the DOD has awarded TBE the initial System Development and Demonstration (“SDD”) phase of the JMDS contract which is worth approximately $14.7 million (of which BIOQUELL’s share is expected to be some $7 million) and will last two years. The SDD phase is reimbursed on a cost plus basis. The DOD’s request for proposal dated 13 March 2007 described a SDD phase which would last two years - and requested firm prices for two production options: the low rate initial production (“LRIP”) option of 23 JMDS units and the full rate production (“FRP”) option of 1,843 units.
Nick Adams BIOQUELL PLC 01264 835 900 
|
